Free. Unsubscribe any time.
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC filed 62 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 16 reporting owners, covering 90 transactions and 999,925 shares. None carries the SEC's AFF10B5ONE flag; all 62 name a plan in a footnote. 7 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-09-15, came on the same day as the one before it (2026-09-15) and reports 3 transactions against 3 in the filing before it.
- The sales it reports total 826 shares, 1,485 fewer than the 2,311 in the filing before it.
- Its 62 plan statements rank 77th of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 62 filings on file run from 2025-01-17 to 2026-09-15, and state 29 plan adoption dates, from 2021-06-10 to 2026-06-10.
Trades in NEUROCRINE BIOSCIENCES INC 90
- Gano Kyle — 2025-01-15 · S · 4,812 shares
- Gano Kyle — 2025-01-15 · S · 60,188 shares
- GORMAN KEVIN CHARLES — 2025-01-27 · S · 146,105 shares
- ABERNETHY MATT — 2025-01-31 · S · 1,283 shares
- BENEVICH ERIC — 2025-01-31 · S · 1,207 shares
- Boyer David W. — 2025-01-31 · S · 1,104 shares
- Cooke Julie — 2025-01-31 · S · 916 shares
- Cooke Julie — 2025-01-31 · S · 824 shares
- Delaet Ingrid — 2025-01-31 · S · 422 shares
- GORMAN KEVIN CHARLES — 2025-01-31 · S · 2,707 shares
- Gano Kyle — 2025-01-31 · S · 1,541 shares
- Lippoldt Darin — 2025-01-31 · S · 1,250 shares
Adoption dates in NEUROCRINE BIOSCIENCES INC 29
- 2021-06-10 — stated in 7 filings
- 2022-09-01 — stated in 7 filings
- 2022-09-12 — stated in 1 filing
- 2022-09-13 — stated in 1 filing
- 2022-09-14 — stated in 1 filing
- 2023-03-15 — stated in 10 filings
- 2023-11-29 — stated in 1 filing
- 2024-03-15 — stated in 1 filing
- 2024-06-14 — stated in 2 filings
- 2024-11-07 — stated in 1 filing
- 2024-11-18 — stated in 2 filings
- 2025-02-24 — stated in 2 filings
Results prints in NEUROCRINE BIOSCIENCES INC 7
- 2025-02-06
- 2025-05-05
- 2025-07-30
- 2025-10-28
- 2026-02-11
- 2026-05-05
- 2026-07-30
Trades before a print in NEUROCRINE BIOSCIENCES INC 3
- 0 days before the 2025-05-05 print — 2025-05-05 · S · RASTETTER WILLIAM H · 30,000 shares
- 2 days before the 2026-07-30 print — 2026-07-28 · S · Norwalk Leslie V · 1,250 shares
- 3 days before the 2025-02-06 print — 2025-02-03 · S · Delaet Ingrid · 623 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · ABERNETHY MATT · 1,283 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · BENEVICH ERIC · 1,207 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Boyer David W. · 1,104 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Cooke Julie · 916 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Cooke Julie · 824 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Delaet Ingrid · 422 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · GORMAN KEVIN CHARLES · 2,707 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Gano Kyle · 1,541 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Lippoldt Darin · 1,250 shares
Interval to NEUROCRINE BIOSCIENCES INC’s next reported results date
How the interval and sources are counted →
- 3within 5 days
- 15within 10 days
- 0shortest, days
- 3no later print
- GORMAN KEVIN CHARLES 2025-01-27 · S · 10 days before the 2025-02-06 print
- ABERNETHY MATT 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Financial Officer
- BENEVICH ERIC 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Commercial Officer
- Boyer David W. 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Corp. Affairs Officer
- Cooke Julie 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Human Resources Officer
- Cooke Julie 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Human Resources Officer
- Delaet Ingrid 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Regulatory Officer
- GORMAN KEVIN CHARLES 2025-01-31 · S · 6 days before the 2025-02-06 print
- Gano Kyle 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Executive Officer
- Lippoldt Darin 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Legal Officer
- Onyia Jude 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Scientific Officer
- ROBERTS EIRY 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Medical Officer
- Delaet Ingrid 2025-02-03 · S · 3 days before the 2025-02-06 print · Chief Regulatory Officer
- RASTETTER WILLIAM H 2025-05-05 · S · 0 days before the 2025-05-05 print
- Norwalk Leslie V 2026-07-28 · S · 2 days before the 2026-07-30 print
Adoption dates NEUROCRINE BIOSCIENCES INC states
- 2021-06-10 in 7 filings
- 2022-09-01 in 7 filings
- 2022-09-12 in 1 filing
- 2022-09-13 in 1 filing
- 2022-09-14 in 1 filing
- 2023-03-15 in 10 filings
- 2023-11-29 in 1 filing
- 2024-03-15 in 1 filing
- 2024-06-14 in 2 filings
- 2024-11-07 in 1 filing
- 2024-11-18 in 2 filings
- 2025-02-24 in 2 filings
- 2025-05-20 in 1 filing
- 2025-06-09 in 3 filings
- 2025-08-06 in 1 filing
- 2025-08-26 in 1 filing
- 2025-08-28 in 1 filing
- 2025-09-03 in 1 filing
- 2025-09-12 in 1 filing
- 2025-09-15 in 3 filings
- 2026-02-13 in 1 filing
- 2026-02-17 in 1 filing
- 2026-02-23 in 2 filings
- 2026-02-25 in 2 filings
- 2026-02-27 in 3 filings
- 2026-03-03 in 1 filing
- 2026-03-06 in 1 filing
- 2026-05-22 in 1 filing
- 2026-06-10 in 1 filing
Filing text: “10b5-1 trading plan adopted by the Reporting Person on March 15, 2024”
Reported results dates on file
- 2025-02-06
- 2025-05-05
- 2025-07-30
- 2025-10-28
- 2026-02-11
- 2026-05-05
- 2026-07-30
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.